2/7/2025
Alumis and ACELYRIN Announce Definitive Merger Agreement in All-Stock Transaction
Key Points:– Alumis and ACELYRIN have agreed to an all-stock merger, creating a well-capitalized biopharmaceutical company focused on advancing immunology treatments.– The combined company will have approximately $737 million in cash and securities, supporting multiple clinical trial readouts and operations into 2027.– Alumis will retain its name and leadership team, with an expanded board including […]
0
3 min read